TH

Theratechnologies

- TSX:TH
Last Updated 2021-09-17

LinkedIn Profile

Access Theratechnologies historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
tsx:th 66356 Mar 1st, 2020 12:00AM Theratechnologies 1.6K 92.00 Open Pharmaceuticals Feb 29th, 2020 08:11PM Feb 29th, 2020 08:11PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 28th, 2020 12:00AM Theratechnologies 1.6K 92.00 Open Pharmaceuticals Feb 28th, 2020 04:54PM Feb 28th, 2020 04:54PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 27th, 2020 12:00AM Theratechnologies 1.6K 92.00 Open Pharmaceuticals Feb 27th, 2020 01:54AM Feb 27th, 2020 01:54AM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 26th, 2020 12:00AM Theratechnologies 1.6K 92.00 Open Pharmaceuticals Feb 26th, 2020 03:29PM Feb 26th, 2020 03:29PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 25th, 2020 12:00AM Theratechnologies 1.6K 92.00 Open Pharmaceuticals Feb 25th, 2020 02:18PM Feb 25th, 2020 02:18PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 24th, 2020 12:00AM Theratechnologies 1.6K 92.00 Open Pharmaceuticals Feb 24th, 2020 12:45PM Feb 24th, 2020 12:45PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 23rd, 2020 12:00AM Theratechnologies 1.6K 92.00 Open Pharmaceuticals Feb 23rd, 2020 05:08PM Feb 23rd, 2020 05:08PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 22nd, 2020 12:00AM Theratechnologies 1.6K 93.00 Open Pharmaceuticals Feb 22nd, 2020 04:03PM Feb 22nd, 2020 04:03PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 21st, 2020 12:00AM Theratechnologies 1.6K 93.00 Open Pharmaceuticals Feb 20th, 2020 08:00PM Feb 21st, 2020 01:41PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4
tsx:th 66356 Feb 19th, 2020 12:00AM Theratechnologies 1.6K 93.00 Open Pharmaceuticals Feb 19th, 2020 12:52PM Feb 19th, 2020 12:52PM Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies'​ strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV. Open Open 2310 Alfred-Nobel Blvd. Montreal Quebec CA H4S 2B4

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.